Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bivalent rLP2086 Vaccine in Adolescents
NCT01299480Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Primary completion
- May 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 2 trial of meningococcal group B vaccine in meningococcal disease, sponsored by Pfizer. Started Mar 2011; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01299480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01299480.